Baxter Awards Caltech Professor $250,000
PASADENA, Calif.— The Hyland Immuno division of Baxter Healthcare Corporation has awarded $250,000 to a California Institute of Technology faculty member to continue his protein design research.
Glendale-based Baxter Hyland Immuno awarded the unrestricted grant to Dr. David Tirrell, the Ross McCollum – William H. Corcoran Professor of Chemistry and Chemical Engineering. Tirrell is also division chair for the Chemistry and Chemical Engineering Division at Caltech.
Tirrell's research addresses the design and synthesis of novel proteins and protein-like materials for applications in biology, biotechnology and medicine. He and his coworkers use biological cells to make proteins, just as nature does, but the cells are reprogrammed to produce specific materials that are targeted toward important biomedical technologies.
"I am delighted by this award, which will allow us to move our research forward much more rapidly," said Tirrell. "The link to Baxter will also help us connect our programs more directly to important clinical problems."
Said Norbert Riedel, PhD, president of Hyland Immuno's recombinant business, "One of the reasons Baxter is in Southern California is the opportunity to collaborate with world-class academic research centers like Caltech. We are pleased to provide this grant to Dr. Tirrell to further his important work in protein design."
Baxter Healthcare Corporation is the principal U.S. subsidiary of Baxter International Inc. (NYSE:BAX), a global medical products and services company that focuses on critical therapies for people with life-threatening conditions. Baxter's medical products and services include blood therapies, medication delivery and renal therapy, and are used by healthcare providers and their patients in more than 100 countries. The Hyland Immuno business of Baxter Healthcare Corporation develops and produces therapeutic proteins from plasma and through recombinant methods to treat hemophilia, immune deficiencies, and other blood-related disorders. Hyland Immuno's portfolio of therapies includes coagulation factors, immune globulins, albumin, wound management products and vaccines.
CONTACT: Jill Perry, Media Relations Director (626) 395-3226 email@example.com
Written by Jill Perry